Literature DB >> 10514286

6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase.

C Doucet1, L Pochet, N Thierry, B Pirotte, J Delarge, M Reboud-Ravaux.   

Abstract

Pyridyl esters of 6-substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid were designed as mechanism-based inhibitors of human leukocyte elastase. Compounds of series 4 specifically inhibited this enzyme. Several of the tested compounds (series 2 and 3) acted as powerful time-dependent inhibitors of both human leukocyte elastase and alpha-chymotrypsin; some compounds of these series inhibited thrombin. Trypsin was not inhibited. A transient inactivation was observed for human leukocyte elastase (k(i)/K(I) = 107 000 M(-1). s(-1) for 4c) and thrombin (k(i)/K(I) = 7 200 M(-1).s(-1) for 3b) as demonstrated by spontaneous or hydroxylamine-accelerated reactivation, irrespective of the nature of the substituent at the 6-position. Conversely, alpha-chymotrypsin was irreversibly inhibited by 6-chloromethyl derivatives (k(i)/K(I) = 107 400 M(-1). s(-1) for 3b). The presence of a latent alkylating function at the 6-position (chloromethyl group) was required for leading to this inactivation. In the absence of such an alkylating function (series 4), human leukocyte elastase was specifically inhibited suggesting that this new series of human leukocyte elastase inhibitors may be of potential therapeutic interest in degradative and degenerative processes involving this enzyme.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514286     DOI: 10.1021/jm990070k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo.

Authors:  I Kempen; D Papapostolou; N Thierry; L Pochet; S Counerotte; B Masereel; J-M Foidart; M Reboud-Ravaux; A Noël; B Pirotte
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

2.  Reversible covalent direct thrombin inhibitors.

Authors:  Mohanram Sivaraja; Nicola Pozzi; Matthew Rienzo; Kenneth Lin; Timothy P Shiau; Daniel M Clemens; Lev Igoudin; Piotr Zalicki; Stephanie S Chang; M Angels Estiarte; Kevin M Short; David C Williams; Anirban Datta; Enrico Di Cera; David B Kita
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.